Commercial tumor drug biotechnology company: ImmunoGen, Inc. (IMGN)

ImmunoGen, Inc. (NASDAQ: IMGN), an immunogen company, was founded in 1980. Headquartered in Waltham, Massachusetts, the United States, it has 277 full-time employees. It is a commercial company Biotechnology Company , focusing on the development and commercialization of antibody drug conjugates (ADC) for cancer patients.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

ImmunoGen (IMGN) US Equities Encyclopedia

ImmunoGen, Inc. (NASDAQ stock code: IMGN) is a biotechnology company focusing on the development of antibody drug conjugate (ADC) therapy for cancer treatment. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

ImmunoGen ADC contains an artificial antibody that can be combined with the target found on cancer cells, and is attached with an effective cytotoxic agent of the company as a "payload". The antibody is used to specifically deliver the cytotoxic agent to cancer cells with its target, and the payload is used to kill these cells. In some cases, the antibody also has anti-cancer activity. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

November 30, 2023, American pharmaceutical company abbvie (AbbVie) announced the acquisition of ImmunoGen for US $10.1 billion. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

ImmunoGen product line/candidate product line

• Mirvetuximab soravtansine (IMGN853), an ADC targeting folate receptor alpha (FRa), is used to treat platinum resistant ovarian cancer; And cell surface proteins expressed in a variety of epithelial tumors, including ovarian cancer, endometrial cancer and non-small cell lung cancer;
• Pivekimab sunirine, an ADC targeting CD123, is currently in the phase II clinical trial for the treatment of acute myeloid leukemia and blastic plasma cell like dendritic cell tumors.

Other candidate product lines include: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

• IMGN529， Targeting CD37 in the treatment of non Hodgkin's lymphoma (NHL)
• IMGN289， Targeting EGFR
• IMGN779 is an antibody drug conjugate (ADC) targeting CD33. It has a new DNA alkylating agent and can act on AML cells
• IMGN632， Anti CD123
• SAR408701 and Sanofi cooperation
• SAR428926 cooperates with Sanofi
• SAR566658 cooperates with Sanofi
• LY3076226 and Lilly cooperation
• PCA062 and Novartis cooperation
• And Amgen Cooperative undisclosed antibody

ImmunoGen cooperation and licensing The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

Companies licensed with ImmunoGen technology include Amgen 、 Bayer HealthCare 、Biotest、 Genentech / Roche 、 Eli Lilly 、 Novartis 、 Sanofi and Takeda 。 The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

Roche's Kadcyla (ado trastuzumab emtansine) uses ImmunoGen's ADC technology. It has been approved and listed in many countries, including the United States, and sold in the United States by Genentech, a member of Roche Group. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html

ImmunoGen (IMGN) US equity investment

The acquisition agreement is reached and will be AbbVie Acquired for US $10.1 billion. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/imgn.html